Figure 2 illustrates how atrosab has shown its therapeutic efficacy in animal models of MS by reducing the cerebral demyelination score in contrast to non-selective TNF alpha blocker which caused further deterioration. The gene discussed is TNF; the disease is myeloid sarcoma.